NEE
54
2
A
44
3
CF
59
3
UPS
51
-5
STI
45
10
APD
44
4
DTE
63
4
MOS
22
6
CHRW
44
2
SO
68
4
KMI
44
-9
DIS
54
2
HAS
52
3
DLTR
27
3
HSY
40
2
FLR
48
6
STT
42
2
GT
43
2
USB
42
2
MHK
43
4
NEE
54
2
A
44
3
CF
59
3
UPS
51
-5
STI
45
10
APD
44
4
DTE
63
4
MOS
22
6
CHRW
44
2
SO
68
4
KMI
44
-9
DIS
54
2
HAS
52
3
DLTR
27
3
HSY
40
2
FLR
48
6
STT
42
2
GT
43
2
USB
42
2
MHK
43
4
Financhill
Back

Kymera Therapeutics Quote, Financials, Valuation and Earnings

How Banks Can Seize Your Accounts

Learn More
Buy
56

KYMR
Kymera Therapeutics

Last Price:
46.12
Seasonality Move:
25.63%

7 Day Trial

ALL ACCESS PASS

$ 7

How this hedge fund manager trades weekly options

Claim your free training on trading weekly options

Kymera Therapeutics Price Quote

$46.12
+0.04 (+3.13%)
(Updated: September 14, 2024 at 6:32 AM ET)

Kymera Therapeutics Key Stats

Buy
56
Kymera Therapeutics (KYMR) is a Buy
Day range:
$44.53 - $46.47
52-week range:
$9.60 - $50.19
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
33.93
P/B ratio:
4.15%
Volume:
321.9K
Avg. volume:
389.7K
1-year change:
137.28%
Market cap:
$2.8B
Revenue:
$78.6M
EPS:
$-2.42

How Much Does Kymera Therapeutics Make?

Is Kymera Therapeutics Growing As A Company?

  • What Is Kymera Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.55%
  • What Is Kymera Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Kymera Therapeutics Stock Price Performance

What Is Kymera Therapeutics 52-Week High & Low?

Kymera Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Kymera Therapeutics?

Is Kymera Therapeutics Cash Flow Positive?

  • What Is KYMR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$106.1M
  • What Is Kymera Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $356.9M
  • What Is Kymera Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$235.5M

Kymera Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KYMR return on invested capital is -30.1%
  • What Is Kymera Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -23.18%
  • What Is KYMR Return On Equity?
    ROE is a measure of profitability and is -30.1%

Kymera Therapeutics Earnings Date & Stock Price

Kymera Therapeutics Competitors

Kymera Therapeutics Dividend Yield

Kymera Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 12.01%
Revenue: 55.33% 104.31%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 55.38
Upside from Last Price: 20.17%

Major Shareholders

  • How many KYMR shares are owned by institutional investors?
    111.8M KYMR shares are owned by institutional investors
  • How many KYMR shares are owned by insiders?
    1.1M KYMR shares are owned by insiders